Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Curi RMB Capital LLC

Curi RMB Capital LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,616 shares of the company’s stock after purchasing an additional 715 shares during the period. Curi RMB Capital LLC’s holdings in Vaxcyte were worth $705,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Whipplewood Advisors LLC acquired a new position in shares of Vaxcyte during the fourth quarter valued at approximately $28,000. Smartleaf Asset Management LLC raised its stake in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new position in Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. grew its holdings in shares of Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after buying an additional 371 shares in the last quarter. Finally, Assetmark Inc. raised its position in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after buying an additional 775 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 32,000 shares of company stock valued at $2,638,800. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PCVX shares. Bank of America dropped their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group dropped their target price on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $30.65 on Monday. The stock has a market capitalization of $3.95 billion, a P/E ratio of -6.66 and a beta of 1.26. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The company has a 50 day moving average price of $60.72 and a 200 day moving average price of $82.64.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. Research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.